MCID: CNT047
MIFTS: 55

Contact Dermatitis

Categories: Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Contact Dermatitis

Summaries for Contact Dermatitis

MalaCards based summary: Contact Dermatitis, also known as contact dermatitis/eczema, is related to irritant dermatitis and nickel allergic contact dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Contact Dermatitis is IL31 (Interleukin 31), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Triamcinolone and Clobetasol have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lymph node, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: 75 Contact dermatitis is a type of acute or chronic inflammation of the skin caused by exposure to chemical... more...

Related Diseases for Contact Dermatitis

Diseases related to Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 871)
# Related Disease Score Top Affiliating Genes
1 irritant dermatitis 33.2 TSLP TNF KRT16 IL4 IL31 IL1B
2 nickel allergic contact dermatitis 33.1 IL5 IL13
3 palladium allergic contact dermatitis 33.0 TNF IL1B
4 allergic contact dermatitis 33.0 TSLP TNF IL5 IL4 IL31 IL1B
5 chromium allergic contact dermatitis 33.0 IL5 IL4 IL13
6 photoallergic dermatitis 33.0 FLG CCR6
7 occupational dermatitis 32.9 IL31 FLG
8 dermatitis 32.4 TSLP TNF KRT16 IL5 IL4 IL31
9 metal allergy 32.3 TNF IL5 IL4 IL1B IL13 FLG
10 cercarial dermatitis 31.9 IL5 IL4
11 dermatitis, atopic 31.8 TSLP TNF IL5 IL4 IL31 IL1B
12 ige responsiveness, atopic 31.8 IL5 IL4 IL13 IFNG
13 urticaria 31.7 TSLP TNF IL5 IL4 IL31 IL1B
14 exanthem 31.7 TNF IL4 IL1B IFNG ICOSLG CCR6
15 erythema multiforme 31.6 TNF IL5 IL4 IL1B IL13 IFNG
16 allergic disease 31.4 TSLP TNF IL5 IL4 IL1B IL13
17 chronic rhinitis 31.4 IL5 IL4 IL13
18 alopecia 31.4 TNF IL4 IL1B IL1A IFNG FLG
19 skin disease 31.3 TSLP TNF KRT17 KRT16 IL5 IL4
20 acne 31.3 TNF IL1RN IL1B IL1A FLG
21 seborrheic dermatitis 31.3 TNF IL1A FLG CCR6
22 dermatophytosis 31.3 TNF IL1B CCR6
23 conjunctivitis 31.2 TNF IL5 IL4 IL13 IFNG CXCL9
24 vitiligo-associated multiple autoimmune disease susceptibility 1 31.1 TNF ICOSLG CCR6
25 allergic rhinitis 31.1 IL5 IL4 IL13 IFNG
26 lichen planus 31.1 TNF KRT16 IL4 IL1B IFNG FLG
27 occupational asthma 31.1 TSLP IL5 IL4 IL13
28 stomatitis 31.1 TNF IL4 IL1B IFNG
29 rhinitis 31.1 TSLP TNF IL5 IL4 IL1B IL13
30 drug allergy 31.0 IL5 IL4 IL13
31 severe cutaneous adverse reaction 31.0 TNF IFNG CCR6
32 purpura 31.0 TNF IL4 IL1B IFNG
33 pulpitis 31.0 TNF IL1B IL1A
34 pustular psoriasis 30.9 TNF IFNG CXCL9 CXCL10
35 proteasome-associated autoinflammatory syndrome 1 30.9 TNF IL5 IL4 IL1RN IL1B IL1A
36 fungal infectious disease 30.9 TNF IL5 IL4 IL1B IL1A IL13
37 allergic asthma 30.9 TSLP IL5 IL4 IL13 IFNG CCR6
38 cellulitis 30.9 TNF IL5 IL1B CCR6
39 folliculitis 30.9 TNF IL5 IL4 IFNG CCR6
40 mycosis fungoides 30.8 IL5 IL4 IFNG CXCR3 CXCL9 CXCL10
41 psoriasis 30.8 TNF KRT17 KRT16 IL5 IL4 IL31
42 primary cutaneous t-cell non-hodgkin lymphoma 30.8 IL5 IL4 IFNG CXCR3 CXCL10 CCR6
43 pemphigoid 30.8 TNF IL5 IL4 IL31 IL1B IL13
44 scabies 30.8 IL5 IL4 IL31 IL13 FLG CCR6
45 covid-19 30.8 TNF IL4 IL1B CXCL10 CCR6
46 skin atrophy 30.8 TNF IL4 IL31 FLG
47 hypereosinophilic syndrome 30.8 IL5 IL4 IL13 IFNG
48 food allergy 30.7 TSLP TNF IL5 IL4 IL13 IFNG
49 type 1 diabetes mellitus 30.7 TNF IL4 IL1B IFNG ICOSLG CXCL10
50 pyoderma 30.7 TNF IL1B CCR6

Graphical network of the top 20 diseases related to Contact Dermatitis:



Diseases related to Contact Dermatitis

Symptoms & Phenotypes for Contact Dermatitis

UMLS symptoms related to Contact Dermatitis:


pruritus; exanthema

MGI Mouse Phenotypes related to Contact Dermatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 CCR6 CXCL10 CXCL9 CXCR3 ICOSLG IFNG
2 immune system MP:0005387 10.16 CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
3 digestive/alimentary MP:0005381 9.92 IFNG IL13 IL4 IL5 KRT16 KRT17
4 hematopoietic system MP:0005397 9.86 CCR4 CCR6 CXCL10 CXCL9 CXCR3 ICOSLG
5 respiratory system MP:0005388 9.76 CCR4 CXCR3 IFNG IL13 IL4 IL5
6 integument MP:0010771 9.32 IFNG IL13 IL1A IL1B IL1RN IL4

Drugs & Therapeutics for Contact Dermatitis

Drugs for Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
3
Glycerin Approved, Investigational Phase 4 56-81-5 753
4
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
5
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
7
Triamcinolone hexacetonide Phase 4
8
Triamcinolone diacetate Phase 4
9
Triamcinolone Acetonide Phase 4 6436
10 Emollients Phase 4
11 Immunosuppressive Agents Phase 4
12 Immunologic Factors Phase 4
13 Calcineurin Inhibitors Phase 4
14
Afamelanotide Approved, Investigational Phase 3 75921-69-6 16132954 16197727
15
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
16
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 4659387 5311101
17
Betamethasone Approved, Vet_approved Phase 2, Phase 3 378-44-9 9782
18
Adalimumab Approved, Experimental Phase 2, Phase 3 331731-18-1
19
Ustekinumab Approved, Investigational Phase 2, Phase 3 815610-63-0
20 Coconut Approved Phase 3
21
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
22
Squaric acid dibutyl ester Investigational Phase 2, Phase 3 2892-62-8
23 Bronchodilator Agents Phase 2, Phase 3
24 Anti-Asthmatic Agents Phase 2, Phase 3
25 Adjuvants, Immunologic Phase 2, Phase 3
26 Betamethasone-17,21-dipropionate Phase 2, Phase 3
27
Betamethasone Valerate Phase 2, Phase 3 2152-44-5
28
Betamethasone sodium phosphate Phase 2, Phase 3
29
Betamethasone benzoate Phase 2, Phase 3
30 Anti-Allergic Agents Phase 2, Phase 3
31 Xhance Phase 2, Phase 3
32 Anesthetics, Local Phase 2, Phase 3
33 Anesthetics Phase 2, Phase 3
34 Respiratory System Agents Phase 2, Phase 3
35 Analgesics Phase 2, Phase 3
36 Antirheumatic Agents Phase 3
37 Interleukin 1 Receptor Antagonist Protein Phase 3
38 Hormones Phase 3
39 Trace Elements Phase 3
40 Micronutrients Phase 3
41 Vitamins Phase 3
42 Calciferol Phase 3
43 Calcium, Dietary Phase 3
44
Calcium Nutraceutical Phase 3 7440-70-2 271
45
Apremilast Approved, Investigational Phase 2 608141-41-9 10151715 11561674
46
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
47
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
48 Anti-Bacterial Agents Phase 2
49 Phosphodiesterase Inhibitors Phase 2
50 Phosphodiesterase 4 Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
2 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
3 Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride allergen patch
4 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
5 Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents Completed NCT00795951 Phase 4
6 The Effects of Dupilumab on Allergic Contact Dermatitis Recruiting NCT03935971 Phase 4 Dupilumab
7 Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis Unknown status NCT01011621 Phase 3 0.5% prednisolone acetate cream;0.1% betamethasone valerate cream
8 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol Completed NCT00640614 Phase 3
9 A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE) Completed NCT04704713 Phase 3 Afamelanotide;Placebo
10 Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering Recruiting NCT05535738 Phase 2, Phase 3 Squaric Acid Dibutyl Ester;Dupilumab;Adalimumab;Ustekinumab;Guselkumab;Canakinumab;Sarilumab;Triamcinolone Acetonide;Betamethasone Valerate;Fluticasone Propionate
11 Comparing Tissue Adhesives in Port Site Closure: A Randomized Controlled Trial Recruiting NCT05492721 Phase 3
12 The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis: A Randomized Controlled Trial With Anakinra vs. Placebo Not yet recruiting NCT05498467 Phase 3 Anakinra;Sodium Chloride 9mg/ml Injection
13 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
14 Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents Withdrawn NCT01518348 Phase 3
15 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study Completed NCT02028208 Phase 2
16 Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study Completed NCT02028182 Phase 2
17 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study Completed NCT00640250 Phase 2
18 A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm Completed NCT00867607 Phase 1, Phase 2 MRX-6;Steroid
19 A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis Completed NCT00931242 Phase 2 Apremilast
20 Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study Completed NCT00132600 Phase 2 bacitracin (allergen)
21 Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for "TRUE Test® Panel 3" - a Phase II, Dose-Response Study. Completed NCT00133341 Phase 2 Goldnatriomthiosulphate, MDBGN, parthenolide
22 Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) Completed NCT03380026 Phase 2 Triamcinolone;Valchlor 0.016 % Topical Gel
23 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis Completed NCT00928447 Phase 2 rHuPH20;Placebo
24 Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations Completed NCT00612768 Phase 2
25 A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis Active, not recruiting NCT03680131 Phase 2 EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
26 A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers Completed NCT02700373 Phase 1 PDC-APB;Placebo
27 A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone Completed NCT03089775 Phase 1 BBI-2000;Vehicle
28 Phase 1 Study to Demonstrate Efficacy of Epikeia Coatings in a Human Clinical Trial Completed NCT00614289 Phase 1
29 A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis Completed NCT01244607 Phase 1 Placebo;NI-0801
30 A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers Completed NCT03375957 Phase 1 ATx201;ATx201 Placebo Gel
31 Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). Completed NCT01529320 Phase 1 Adventan® (methylprednisolone aceponate 0,1%)
32 A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure Not yet recruiting NCT04853823 Phase 1 PDC-APB
33 Bariederm Cream in Chronic Contact Dermatitis Unknown status NCT02026700
34 Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation Unknown status NCT00445029
35 Nickel Desensitization Using Topical Therapy Unknown status NCT01413477 Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
36 The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population Unknown status NCT02614248
37 Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects Completed NCT00929981 Tablet Methylprednisolone (4 or 16 mg)
38 Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study Completed NCT03313232
39 Evaluation of the Clinical Implication of Short Repeated Nickel Exposures Completed NCT03309215
40 Exploratory Study of Natural Killer Cells in Human Skin Completed NCT00824889
41 Specific Factors Associated With the Development of Incontinence- Associated Dermatitis (IAD) in ICU Patients Suffering From Fecal Incontinence: Matched Case Control Study Completed NCT02996357
42 An Open Label Study of the Therapeutic Effects of Tetrix Cream in Allergic Contact and Irritant Contact Dermatitis Completed NCT00646867
43 Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis Completed NCT03685929
44 Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel Completed NCT04365140
45 Comparison of the Effectiveness and Safety Between Moisturizing Cream Containing Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Hermatitis in Intensive Care Unit Nurses: a Double Blind Randomized Clinical Trial Completed NCT04218500
46 Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study Completed NCT03902392
47 Epidemiology and Co-Reactivity of Novel Surfactant Allergens Completed NCT02534441
48 Regional Differences of Cutaneous Irritation and Its Effect on Skin Barrier Recovery: A Randomised, Controlled Trial Completed NCT03231813
49 Children With Aluminium Contact Allergy: Cutaneous Exposure Study Completed NCT04438135
50 Molecular and Cellular Characterization of Spongiotic Dermatitis Completed NCT00371163

Search NIH Clinical Center for Contact Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


pramoxine
Pramoxine hydrochloride

Cochrane evidence based reviews: dermatitis, contact

Genetic Tests for Contact Dermatitis

Anatomical Context for Contact Dermatitis

Organs/tissues related to Contact Dermatitis:

MalaCards : Skin, T Cells, Lymph Node, Eye, Neutrophil, Myeloid, Spinal Cord

Publications for Contact Dermatitis

Articles related to Contact Dermatitis:

(show top 50) (show all 15032)
# Title Authors PMID Year
1
Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. 53 62
19538184 2009
2
Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. 53 62
18637008 2008
3
Protein contact dermatitis: allergens, pathogenesis, and management. 53 62
18845114 2008
4
Polymorphisms in the interleukin-1 gene influence the stratum corneum interleukin-1 alpha concentration in uninvolved skin of patients with chronic irritant contact dermatitis. 53 62
18416755 2008
5
Allergies in India: an analysis of 3389 patients attending an allergy clinic in Mumbai, India. 53 62
18828339 2008
6
Allergic contact dermatitis from natural rubber latex in atopic dermatitis and the risk of later Type I allergy. 53 62
15982232 2005
7
Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments. 53 62
15059180 2004
8
Expression of CS-1 fibronectin precedes monocyte chemoattractant protein-1 production during elicitation of allergic contact dermatitis. 53 62
12911787 2003
9
Nickel-induced cytokine production from mononuclear cells in nickel-sensitive individuals and controls. Cytokine profiles in nickel-sensitive individuals with nickel allergy-related hand eczema before and after nickel challenge. 53 62
10929769 2000
10
Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. 53 62
10651994 2000
11
The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. 53 62
10504443 1999
12
Chromium induced contact dermatitis and indices for diagnosis. 53 62
17219860 1999
13
Keratin 17 is expressed during the course of SLS-induced irritant contact dermatitis, but unlike keratin 16, the degree of expression is unrelated to the density of dividing keratinocytes. 53 62
9686973 1998
14
In vivo cytokine profiles in allergic and irritant contact dermatitis. 53 62
8654078 1995
15
Cell-bound IgE and increased expression of Fc epsilon-receptors on dendritic cells in cutaneous infiltrates of mycosis fungoides. 53 62
1834378 1991
16
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. 62
36387062 2023
17
Management of Allergic Skin Disorders in Pregnancy. 62
36410998 2023
18
Proteolytic activity accelerates the TH17/TH22 recall response to an epicutaneous protein allergen-induced TH2 response. 62
35378053 2022
19
Hydroquinone Induced Skin Irritant Reaction Could Be Achieved by Activating Mast Cells via Mas-related G protein-coupled receptor X2. 62
36463492 2022
20
Cheilitis caused by allergic contact dermatitis to cinnamon in chai tea: a case report. 62
36461791 2022
21
Severe symptomatic nickel allergy following stent graft implantation requiring excision and external iliac artery reconstruction. 62
36248398 2022
22
Occupational dermatoses: knowledge, attitudes and perceptions among motor vehicle repair workers. 62
34340635 2022
23
Occupational allergic contact dermatitis caused by colophonium, an unsuspected sensitizer in a petrochemical worker. 62
36050864 2022
24
Allergic contact dermatitis from resacetophenone (2',4'-dihydroxyacetophenone; CAS no. 89-84-9) in an antifungal nail preparation. 62
35980321 2022
25
Alopecia areata after severe allergic contact dermatitis to a permanent hair dye. 62
35984243 2022
26
Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: A case report. 62
35980345 2022
27
T cells in resolved allergic contact dermatitis steer tissue inflammation and MMP-12-driven tissue modulation. 62
35984563 2022
28
A cross-sectional study of contact allergens in feminine hygiene wipes: a possible cause of vulvar contact dermatitis. 62
36448019 2022
29
A case of generalized allergic contact dermatitis due to sodium lauroyl methylaminopropionate in a shampoo. 62
36042564 2022
30
Contact dermatitis to undergarments. 62
36458656 2022
31
Airborne contact dermatitis to epoxy resin for creating herbarium. 62
36461679 2022
32
Contact Dermatitis From Amplified Hand Hygiene Practices in the COVID-19 Pandemic Among Medical Students: Frequency, Knowledge, and Attitude. 62
36473521 2022
33
A systematic review of allergic and irritative contact dermatitis of the vulva: the most important allergens/irritants and the role of patch testing. 62
36458568 2022
34
Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation. 62
36161697 2022
35
Reevaluating Corticosteroid Classification Models in Patient Patch Testing. 62
36169950 2022
36
Results of the patch tests with European baseline series in children: Five years of experience from a single center in Turkey and a review of the literature. 62
36437575 2022
37
Review of aluminum, paraben, and sulfate product disclaimers on personal care products. 62
34144080 2022
38
Formaldehyde Release From Eyelash Glues: Analysis Using the Chromotropic Acid Method. 62
35674514 2022
39
Patch testing with the European baseline series and 10 added allergens: Single-centre study of 748 patients. 62
35736503 2022
40
Quantitative risk assessment of allergens leaching from menstrual hygiene products. 62
36067853 2022
41
Systematic Review of Systemic Corticosteroid Effects on Patch Testing. 62
36255380 2022
42
Adverse reactions to cosmetics reported to the Chongqing adverse drug reaction monitoring centre system in China. 62
36385252 2022
43
The role of topical capsaicin gel in pain management during microfocused ultrasound treatment for neck laxity. 62
36382669 2022
44
Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019-2021 epidemiological situation. 62
36403138 2022
45
Allergic contact dermatitis from vitamins: A systematic review. 62
36210883 2022
46
Non-occupational allergic contact dermatitis from epoxy resin in children's games. 62
36444522 2022
47
Topical eye medications causing allergic contact dermatitis. 62
36382619 2022
48
Too Much of a Good Thing? Allergic Contact Dermatitis to Pimecrolimus. 62
35318979 2022
49
Allergic contact dermatitis due to excipients in topical drugs. 62
36331181 2022
50
Pustular Allergic Contact Dermatitis Caused by a Topical Probiotic. 62
36399531 2022

Variations for Contact Dermatitis

Expression for Contact Dermatitis

Search GEO for disease gene expression data for Contact Dermatitis.

Pathways for Contact Dermatitis

Pathways related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TSLP TNF IL5 IL4 IL31 IL1RN
2
Show member pathways
13.87 TNF IL5 IL4 IL1B IL1A IL13
3
Show member pathways
13.54 TNF IL5 IL4 IL1B IL1A IL13
4
Show member pathways
13.47 CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
5
Show member pathways
13.45 TNF IL5 IL4 IL1B IL1A IL13
6
Show member pathways
13.32 CCL22 CXCL10 IFNG IL13 IL1A IL1B
7
Show member pathways
13.28 TNF IL5 IL4 IL1B IL1A IL13
8
Show member pathways
12.89 CXCR3 CXCL9 CXCL10 CCR6 CCR4 CCL22
9
Show member pathways
12.84 TNF IL1B IL1A CXCL9 CXCL10
10
Show member pathways
12.7 TNF IL5 IL4 IL1B IL1A IL13
11 12.63 TNF IL4 IL1RN IL1B IFNG CXCL10
12
Show member pathways
12.52 CXCL10 IFNG IL1A IL1B IL1RN IL4
13
Show member pathways
12.51 IL4 IL1RN IL1B IL1A IL13
14
Show member pathways
12.43 IL5 IL1B IL1A IL13
15
Show member pathways
12.31 TNF IL1B IL1A IFNG
16 12.24 TNF IL1RN IL1B IL1A IL13
17 12.21 TNF IL4 IL1B IL1A IL13 IFNG
18
Show member pathways
12.17 TNF IL5 IL4 IFNG
19
Show member pathways
12.16 CXCR3 CXCL9 CXCL10 CCR6 CCR4 CCL22
20 12.1 TNF IL4 IL1B IL1A IFNG CXCL10
21
Show member pathways
12.06 IL5 IL1B IL1A IL13
22 12.06 TNF IL4 IL1B IL1A IL13 CCL22
23 12.03 TNF IL5 IL4 IFNG
24 11.89 KRT17 IL5 IL4 IL13 IFNG
25 11.89 TNF IL5 IL4 IL1B IL1A IL13
26
Show member pathways
11.85 IL4 IL1B IFNG
27 11.81 TNF IL4 IFNG ICOSLG
28 11.8 IL13 IL1B IL4 IL5 TNF
29
Show member pathways
11.79 TNF IL1B IFNG
30
Show member pathways
11.78 TNF IL5 IL4 IFNG
31 11.76 TNF IL1B FLG
32 11.75 TNF IL1B IFNG
33
Show member pathways
11.75 TNF IL1B IL1A IFNG
34
Show member pathways
11.73 TNF IL5 IL4 IL1A IL13 IFNG
35 11.72 IL4 IL1B IFNG
36 11.71 IL5 IL4 IFNG
37 11.66 IL1A IL1B TNF
38 11.59 TNF IL1B IL1A IFNG
39 11.55 TNF IL1B IFNG
40 11.55 CCL22 CXCL10 IL1A IL1B IL1RN TNF
41 11.51 IL5 IL4 IL31 IL13 IFNG CCL22
42 11.5 CXCL10 CXCL9 IFNG IL1B
43 11.47 IL1RN IL1B IL1A
44 11.4 TNF IL1B IL1A
45 11.37 IL5 IL4 IFNG
46 11.36 TNF IL1B IL1A CXCL9 CXCL10
47 11.33 IL5 IL4 IL13 IFNG
48 11.32 TNF IL5 IL4 IL13 IFNG
49 11.29 CXCL10 CXCL9 CXCR3
50 11.2 TSLP TNF IL5 IL4 IL1B IL13

GO Terms for Contact Dermatitis

Cellular components related to Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.25 TSLP TNF IL5 IL4 IL31 IL1RN
2 external side of plasma membrane GO:0009897 9.86 CCR4 CCR6 CXCL10 CXCL9 CXCR3 ICOSLG
3 extracellular space GO:0005615 9.74 TSLP TNF IL5 IL4 IL31 IL1RN

Biological processes related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.46 TNF IL4 IL1B IL1A IL13 IFNG
2 signal transduction GO:0007165 10.27 CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
3 positive regulation of inflammatory response GO:0050729 10.22 TSLP TNF IL1B IFNG
4 cellular response to lipopolysaccharide GO:0071222 10.2 TNF IL1B IL1A CXCL9 CXCL10
5 response to virus GO:0009615 10.19 TNF IFNG CXCL10 CCL22
6 calcium-mediated signaling GO:0019722 10.19 TNF CXCR3 CCR6 CCR4
7 neutrophil chemotaxis GO:0030593 10.18 IL1B CXCL9 CXCL10 CCL22
8 positive regulation of phagocytosis GO:0050766 10.16 TNF IL1B IFNG
9 regulation of insulin secretion GO:0050796 10.16 TNF IL1B IFNG
10 positive regulation of interleukin-6 production GO:0032755 10.16 TSLP TNF IL1B IL1A IFNG
11 positive regulation of B cell proliferation GO:0030890 10.15 IL5 IL4 IL13
12 chemotaxis GO:0006935 10.15 CXCR3 CXCL9 CXCL10 CCR6 CCR4 CCL22
13 positive regulation of nitric oxide biosynthetic process GO:0045429 10.14 TNF IL1B IFNG
14 positive regulation of interleukin-10 production GO:0032733 10.14 TSLP IL4 IL13
15 defense response GO:0006952 10.12 TNF ICOSLG CXCL9 CXCL10
16 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.11 IL1A IL1B TNF
17 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.11 IL4 IL1B IL1A
18 cell chemotaxis GO:0060326 10.11 CCL22 CCR4 CCR6 CXCR3
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.1 TSLP TNF IL4 IL13 IFNG
20 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 10.09 IL13 CXCL9 CXCL10
21 positive regulation of mitotic nuclear division GO:0045840 10.09 TNF IL1B IL1A
22 positive regulation of cytokine production GO:0001819 10.08 IFNG IL1A IL1B TNF
23 response to bacterium GO:0009617 10.06 TNF CXCL9 CXCL10 CCR4
24 response to lipopolysaccharide GO:0032496 10.05 TNF IL1B IL1A IL13 CXCL10
25 microglial cell activation GO:0001774 10.03 IFNG IL13 IL4 TNF
26 chemokine-mediated signaling pathway GO:0070098 10.03 CCL22 CCR4 CCR6 CXCL10 CXCL9 CXCR3
27 inflammatory response GO:0006954 10.03 CCL22 CCR4 CXCL10 CXCL9 CXCR3 IL13
28 positive regulation of chemokine production GO:0032722 10.02 TSLP TNF IL1B IFNG
29 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10 TNF IL1B IFNG
30 neuroinflammatory response GO:0150076 9.98 IL4 IFNG
31 positive regulation of immature T cell proliferation in thymus GO:0033092 9.97 IL1B IL1A
32 positive regulation of mononuclear cell migration GO:0071677 9.97 IL4 TNF
33 astrocyte activation GO:0048143 9.97 IFNG IL1B TNF
34 positive regulation of fever generation GO:0031622 9.96 IL1B TNF
35 cellular response to interleukin-17 GO:0097398 9.95 IL1B CXCL10
36 sequestering of triglyceride GO:0030730 9.93 TNF IL1B
37 fever generation GO:0001660 9.91 IL1A IL1B
38 positive regulation of nitrogen compound metabolic process GO:0051173 9.9 IFNG TNF
39 negative regulation of complement-dependent cytotoxicity GO:1903660 9.89 IL13 IL4
40 positive regulation of vitamin D biosynthetic process GO:0060557 9.86 TNF IFNG
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.8 TNF IL1B IFNG
42 immune response GO:0006955 9.7 TNF IL5 IL4 IL1RN IL1B IL1A

Molecular functions related to Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-C chemokine binding GO:0019957 9.85 CXCR3 CCR6 CCR4
2 C-C chemokine receptor activity GO:0016493 9.73 CXCR3 CCR6 CCR4
3 CXCR3 chemokine receptor binding GO:0048248 9.71 CXCL9 CXCL10
4 cytokine activity GO:0005125 9.7 TSLP TNF IL5 IL4 IL31 IL1RN
5 chemokine receptor activity GO:0004950 9.63 CXCR3 CCR6 CCR4
6 cytokine receptor binding GO:0005126 9.62 IL4 IL31 IL13
7 interleukin-1 receptor binding GO:0005149 9.35 IL1A IL1B IL1RN

Sources for Contact Dermatitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....